Stock TERN TERNS PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Terns Pharmaceuticals, Inc.

Equities

TERN

US8808811074

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-28 pm EDT 		5-day change 1st Jan Change
6.32 USD +5.33% Intraday chart for Terns Pharmaceuticals, Inc. +3.27% -2.62%
May. 13 Terns Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
May. 08 Terns Pharmaceuticals, Inc. Announces Executive Changes CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Terns Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Terns Pharmaceuticals, Inc. Announces Executive Changes
Terns Pharmaceuticals, Inc. Announces Data from Ongoing Phase 1 Pharmacokinetic Study of Allosteric BCR-ABL Inhibitor Tern-701 in Adult Healthy Volunteers and Highlights Potential for Competitive Differentiation
Terns Pharmaceuticals, Inc. Appoints Melita Sun Jung as Chief Business Officer
Terns Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Terns Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
Terns Pharmaceuticals Gets Orphan Drug Label for Chronic Myeloid Leukemia Treatment Candidate
Terns Pharmaceuticals, Inc. Appoints Amy Burroughs as Chief Executive Officer
Terns Pharmaceuticals, Inc. Appoints Amy Burroughs as Member of Board of Directors
Terns Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Terns Pharmaceuticals, Inc. Announces First Participant Dosed in Phase 1 Clinical Trial of TERN-601 Oral GLP-1 Receptor Agonist for Treatment of Obesity
Terns Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Terns Pharmaceuticals, Inc. Achieves Primary Endpoint and All Secondary Endpoints in Phase 2a DUET Trial of THR-ß Agonist TERN-501 in NASH
Terns Pharmaceuticals, Inc. Announces Leadership Transition
Terns Pharmaceuticals Announces Leadership Transition
Sector Update: Health Care Stocks Lean Lower Premarket Tuesday
Terns Pharmaceuticals Says New Preclinical Data of TERN-601 Shows Improved Glucose Tolerance in Mouse Model
Terns Pharmaceuticals, Inc. Highlights New Preclinical Data for TERN-601 Program in Obesity at the ADA’s 83rd Annual Scientific Session
Terns Pharmaceuticals Offers 35% Upside With $1 Billion-Plus Products in Pipeline, Upcoming NASH Data, Mizuho Says
Terns Pharmaceuticals Q1 Net Loss per Share Narrows
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. TERN Stock
  4. News Terns Pharmaceuticals, Inc.
  5. Other languages